Literature DB >> 9120272

Degenerate MHC restriction reveals the contribution of class I MHC molecules in determining the fine specificity of CTL recognition of an immunodominant determinant of HIV-1 gp160 V3 loop.

M Shirai1, S Kozlowski, D H Margulies, J A Berzofsky.   

Abstract

The novel allogeneic presentation of an immunodominant determinant within the HIV-1 gp160 V3 loop by three different class I MHC molecules to the same CD8+ CTL is used to study the influence of the MHC molecule on the fine specificity of CTL recognition. We previously reported that four distinct class I molecules of H-2d,u,p,q presented the V3 decapeptide P18-I10 (RGPGRAFVTI) to CTL. Surprisingly, we found that H-2d,u,p cells mutually cross-present the P18-I10 peptide to allogeneic CTL clones of each of the other haplotypes, whereas none of these cross-presents to H-2q CTL, nor do H-2q targets present to CTL of the other haplotypes. Here, we explore the critical amino acid residues for the cross-presentation using 10 variant peptides with single amino acid substitutions. The fine specificity examined using these mutant peptides presented by the same MHC class I molecule showed striking similarity among the CTL of each haplotype, expressing either V beta 8.1 or V beta 14. In contrast, the fine specificity is different between the distinct MHC class I molecules even for the lysis by the same CTL, as shown by reciprocal effects of the same substitutions. Thus, peptide fine specificity of a single TCR is influenced by changes in the class I MHC molecules presenting the Ag.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9120272

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

1.  Delivery of DNA HIV-1 vaccine to the liver induces high and long-lasting humoral immune responses.

Authors:  Milan Raska; Zina Moldoveanu; Jan Novak; Zdenek Hel; Lea Novak; Jadranka Bozja; Richard W Compans; Chinglai Yang; Jiri Mestecky
Journal:  Vaccine       Date:  2008-02-07       Impact factor: 3.641

2.  Expression of human immunodeficiency virus type 1 gp120 from herpes simplex virus type 1-derived amplicons results in potent, specific, and durable cellular and humoral immune responses.

Authors:  Peter K Hocknell; Rebecca D Wiley; Xiuqing Wang; Thomas G Evans; William J Bowers; Tomas Hanke; Howard J Federoff; Stephen Dewhurst
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

3.  High-level primary CD8(+) T-cell response to human immunodeficiency virus type 1 gag and env generated by vaccination with recombinant vesicular stomatitis viruses.

Authors:  Karl Haglund; Ingrid Leiner; Kristen Kerksiek; Linda Buonocore; Eric Pamer; John K Rose
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

4.  Robust recall and long-term memory T-cell responses induced by prime-boost regimens with heterologous live viral vectors expressing human immunodeficiency virus type 1 Gag and Env proteins.

Authors:  Karl Haglund; Ingrid Leiner; Kristen Kerksiek; Linda Buonocore; Eric Pamer; John K Rose
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

5.  Gag protein epitopes recognized by ELA-A-restricted cytotoxic T lymphocytes from horses with long-term equine infectious anemia virus infection.

Authors:  W Zhang; S M Lonning; T C McGuire
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

6.  Hybrid alphavirus-rhabdovirus propagating replicon particles are versatile and potent vaccine vectors.

Authors:  Nina F Rose; Jean Publicover; Anasuya Chattopadhyay; John K Rose
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-07       Impact factor: 11.205

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.